A new approach to non-Hodgkin's lymphoma

Internal Medicine

Volumn 39, Issue 3, 2000, Pages 197-208

  Hauke, Ralph J ^a,b   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Classification; Pathogenesis; Review; Treatment

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; VINCRISTINE SULFATE;

B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; FOLLICULAR LYMPHOMA; GENOTYPE; HUMAN; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; ONCOGENE; REVIEW; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS;

EID: 0034034337     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.39.197     Document Type: Review

References (62)

1. Armitage JO. The changing classification of Non-Hodgkin's lymphomas. CA Cancer J Clin 47 (6): 323-325, 1997.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 48: 6-29, 1998.
3. Weisenburger DD. Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Annals Oncol 5 (S19): 1994.
4. Gaidano G, Dalla-Favera R. Molecular biology of lymphomas. In: DeVita VT, ed. Cancer: Principles and Practice of Oncology, 5th edition. Lippincott-Raven Publishers, Philadelphia, 1997.
5. Rappaport H. Tumors of the hematopoietic system. Atlas of Tumor Pathology, Section III, Fascicle 8. Washington, D.C. Armed Forces Institute of Pathology, 1966.
6. Koeppen H, Vardiman JW. New entities, issues and controversies in the classification of malignant lymphomas. Semin Oncol 25 (4): 421-434, 1998.
7. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink H-A. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Am J Clin Path 111 (S1): S8-S12, 1999.
8. Frizzera G, Wu C, Inghirami G. The usefulness of immunophenolypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. Am J Clin Path 111 (Suppl. 1): S13-S39, 1999.
9. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 89 (11): 1361-1392, 1994.
10. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89 (11): 3909-3918, 1997.
11. Dug T, Le Beau MM. Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma. Semin Oncol 25: 447-460, 1998.
12. Lyons SF, Liebowitz DN. The roles of human viruses in the pathogenesis of lymphoma. Semin Oncol 25: 461-475, 1998.
13. McKnight JLC, Cen H, Riddler SA, et al. EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in posttransplant lymphoproliferative disorders. Leuk Lymphoma 15: 9-16, 1994.
14. Mazzaro C, Efremor DG, Burrone D, et al. Hepatitis C virus, mixed cryoglobulinemia and non-Hodgkin's lymphoma. Ital J Gastroenterol Hepatol 30 (4): 428-434, 1998.
15. Dutta U, Raia V, Gargn PX, et al. A prospective study on the incidence of hepatitis B and C infections amongst patients with lymphoproliferative disorders. Indian J Med Res 107: 78-82, 1998.
16. King PD, Wilkes JD, Diaz-Arias AA. Hepatitis C virus infection in non-Hodgkin's lymphoma. Clin Lab Haematol 20 (2): 107-110, 1998.
17. Ellenreider V, Weidenbach H, Frickhofen N, et al. Hepatitis C and Hepatitis G virus in B-cell non-Hodgkin's lymphoma. J Hepatol 28 (1): 34-39, 1998.
18. Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med 106: 222-226, 1999.
19. Zucca E, Bartoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid tissue lymphoma. N Engl J Med 335(12): 804-809, 1998.
20. Baars JW, de Jong D, Willemse EM, et al. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification. Br J Cancer 79(11-12): 1770-1776, 1999.
21. Gacoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90 (1): 244-251, 1997.
22. LeBlond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16: 2052-2059, 1998.
23. Cesarman E, Cgadburn A, Liu Y-F, et al. BCL-6 mutations in posttransplant lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 92 (7): 2294-2302, 1998.
24. Kinney MC, Kadin ME. The pathological and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am J Clin Pathol 111 (Suppl. 1): S56-S67, 1999.
25. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93 (8): 2697-2708, 1999.
26. Friedman AS, Nadler LM. Malignancies of lymphoid cells. In Harrison's Principles of Internal Medicine, 14th edition, Fauci AS, et al (editors). McGraw-Hill. New York, 1998: 700.
27. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 31: 1860-1861, 1971.
28. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994, 1993.
29. Hermans J, Krol ADG, van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86: 1460-1463, 1995.
30. Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85 (12): 3671-3678, 1995.
31. Miller TP, LeBlanc M, Grogan TM, Fisher RI. Follicular lymphomas: do histologic subtypes predict outcome? Hematol Oncol Clin North Am Oct 11 (5): 893-900, 1997.
32. Vose JM. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 25: 483-491, 1998.
33. Bierman PJ, Armitage JO. Non-Hodgkin's lymphoma. Curr Opin Hematol 3: 266-272, 1996.
34. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 328: 1023-1030, 1993.
35. Schultze JL, Nadler LM. T-cell mediated immunotherapy for B-cell lymphoma. J Mol Med 77: 322-331, 1999.
36. Hiddemann W, Griesunger F, Unterhalt M. Interferon alfa for the treatment of follicular lymphomas. Cancer J Sci Am 4 (Suppl. 2): S13-S18, 1998.
37. MacManus MP, Hoppe RT. Overview of treatment of localized low-grade lymphomas. Hematol Oncol Clin North Am 11 (5): 901-918, 1997.
38. Laport GF, Williams SF. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 25 (4): 503-517, 1998.
39. Freedman A, Gribben J, Rabinowe S, et al. Autologous bone marrow transplantation in advanced low-grade B-cell non-Hodgkin's lymphoma in first remission. Blood 82: 1313a, 1993.
40. Freedman AS, Ritz J, Neuberg D, et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade non-Hodgkin's lymphoma. Blood 77 (11): 2524-2529, 1997.
41. Rohatiner AZS, Johnson PWM, Price CGA, et al. Mycloablative therapy with autologous hone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12 (6): 1177-1184, 1994.
42. Van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92 (5): 1832-1836, 1998.
43. Verdonck LF, Dekker AW, Lokhorst HM, et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 90 (10): 4201-1205, 1997.
44. Mandigers CMPW, Raemekers JMM, Schattenberg AVMB, et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Brit J Haemat 100: 198-206, 1998.
45. Vose JM, Bierman PJ, Lynch JC, et al. Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma. J Clin Oncol 16 (3): 844-849, 1998.
46. Anderson JR, Vose JM, Bierman PJ, et al. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol 11 (2): 218-224, 1993.
47. Rodriquez J, McLaughlin P, Hagemeister FB, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93 (7): 2202-2207, 1999.
48. Talman MS, Hakimian D. Purine nucleoside analogues: emerging roles in indolent lymphoproliferative disorders. Blood 86: 1710-1716, 1995.
49. Solal-Ceeligny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a mullicenter study by the Groupe L'Etude des Lymphomes de l'Adulte. J Clin Oncol 14: 514-519, 1996.
50. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (8): 2825-2833, 1998.
51. Miller TP, Dahlberg S, Cassady JR, et al. Three cycles of CHOP plus radiotherapy is superior to eight cycles of CHOP alone for localized intermediate and high grade non-Hodgkin's lymphoma (NHL): a Southwest Oncology Group study. Proc Am Soc Clin Oncol 15: 1257a, 1996 (Abstract).
52. Glick JH, Kim K, Earle J, et al. An ECOG randomized phase III trial of CHOP vs. CHOP+ radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 14: 1221a, 1995 (Abstract).
53. Fisher RJ, Gaynos ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006, 1993.
54. Philip T, Guglielmi C, Hagenbrook A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333: 1540-1545, 1995.
55. Haioun C, Lepage E, Gisselbracht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 12: 2543-2551, 1994.
56. Haioun C, Lepage E, Gisselbricht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 15: 1131-1137, 1997.
57. Gianni AM, Bregni M, Siena S, et al. High dose chemotherapy and autologous hone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290-1297, 1997.
58. Santini G, Salvango L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 16 (8): 2796-2802, 1998.
59. Shin SS, Sheibani K, Fishleder A, et al. Monocytoid B-cell lymphoma in patients with Sjögren's syndrome: a clinicopathologic study of 13 patients. Hum Pathol 22: 422-430, 1991.
60. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD plus high dose methotrexale/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol 16 (12): 3803-3809, 1998.
61. Stewart DA, Vose JM, Weisenberger D, et al. The role of high-dose therapy and autologous hematopoietic stem cell rescue for mantle cell lymphoma. Ann Oncol 6: 263-266, 1995.
62. Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response in 48 patients. Eur J Haematol 62 (2): 76-82, 1999.